Next Article in Journal
New Data on Vaccine Antigen Deficient Bordetella pertussis Isolates
Next Article in Special Issue
Micelle-Based Adjuvants for Subunit Vaccine Delivery
Previous Article in Journal
The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
Previous Article in Special Issue
Gas Vesicle Nanoparticles for Antigen Display
Article

Chitosan-Poly (I:C)-PADRE Based Nanoparticles as Delivery Vehicles for Synthetic Peptide Vaccines

1
Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
2
Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Av. Barcelona s/n, Campus Vida, University of Santiago de Compostela, 15707 Santiago de Compostela, Spain
3
Laboratory of Cellular Oncology, National Cancer Institute, NIH, Bethesda, MD, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Darrell J. Irvine
Vaccines 2015, 3(3), 730-750; https://doi.org/10.3390/vaccines3030730
Received: 1 July 2015 / Revised: 14 August 2015 / Accepted: 31 August 2015 / Published: 11 September 2015
(This article belongs to the Special Issue Nanoparticle-Based Vaccines)
The safety and precision of peptide antigens has prompted the search for adjuvants capable of increasing the immune response against these intrinsically poorly immunogenic antigens. The integration of both immunostimulants and peptide antigens within nanometric delivery systems for their co-delivery to immune cells is a promising vaccination strategy. With this in mind, the potential synergistic effect of the immunostimulant poly (I:C) (pIC) and a T-Helper peptide (PADRE), integrated into a chitosan (CS) based nanostructure, was explored. The value of this nanostructured combination of materials was assessed for a peptide antigen (1338aa) derived from the HPV-16 L2 protein. These nanoparticles, produced by ionic gelation technique, exhibited a nanometric size (<300 nm), a high positive surface charge (>40 mV) and high pIC association efficiency (>96%). They also showed capacity for the association of both the 1338aa and PADRE peptides. The influence of the presence of pIC and PADRE in the nanocomposition, as well as that of the peptide presentation form (encapsulated versus surface adsorbed) on the antibody induction was evaluated in a preliminary in vivo study. The data obtained highlights the possibility to engineer nanoparticles through the rational combination of a number of adjuvant molecules together with the antigen. View Full-Text
Keywords: peptide-based antigens; nanoparticle; adjuvant; chitosan; poly (I:C); HPV; T-Helper peptide peptide-based antigens; nanoparticle; adjuvant; chitosan; poly (I:C); HPV; T-Helper peptide
Show Figures

Graphical abstract

MDPI and ACS Style

Correia-Pinto, J.F.; Csaba, N.; Schiller, J.T.; Alonso, M.J. Chitosan-Poly (I:C)-PADRE Based Nanoparticles as Delivery Vehicles for Synthetic Peptide Vaccines. Vaccines 2015, 3, 730-750. https://doi.org/10.3390/vaccines3030730

AMA Style

Correia-Pinto JF, Csaba N, Schiller JT, Alonso MJ. Chitosan-Poly (I:C)-PADRE Based Nanoparticles as Delivery Vehicles for Synthetic Peptide Vaccines. Vaccines. 2015; 3(3):730-750. https://doi.org/10.3390/vaccines3030730

Chicago/Turabian Style

Correia-Pinto, Jorge F., Noemi Csaba, John T. Schiller, and Maria J. Alonso. 2015. "Chitosan-Poly (I:C)-PADRE Based Nanoparticles as Delivery Vehicles for Synthetic Peptide Vaccines" Vaccines 3, no. 3: 730-750. https://doi.org/10.3390/vaccines3030730

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop